GlassScriptPhysician profile
Hal M Weitzbuch
NPI 1669629317
$470,791.25
in general payments reported to CMS, 2019-2025
40 companies · $160K in 2025
The $160K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $17K · 2021: $4,298 · 2022: $30K · 2023: $126K · 2024: $68K · 2025: $160K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $291K · Consulting Fee: $29K · Travel and Lodging: $20K · Food and Beverage: $13K · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $290,786.75 |
| Consulting Fee | $28,945.50 |
| Travel and Lodging | $20,125.86 |
| Food and Beverage | $13,260.64 |
| Education | $362.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $130,339.61 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Genzyme Corporation | $100,591.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $92,195.13 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $50,729.69 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $43,943.13 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $28,164.56 | 2023-2025 | Zoryve |
| Dermira, INC. | $16,439.24 | 2019-2021 | |
| Leo Pharma INC. | $2,389.49 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $956.88 | 2019-2025 | Botox, Skyrizi, Humira |
| Sun Pharmaceutical Industries INC. | $559.01 | 2019-2025 | Winlevi, Ilumya |
| Kowa Pharmaceuticals America, INC. | $550.00 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $413.02 | 2019-2024 | Xtrac |
| Allergan, INC. | $404.11 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $363.49 | 2019-2024 | |
| Journey Medical Corporation | $347.76 | 2022-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $328.92 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $314.40 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $227.34 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $208.87 | 2022-2025 | Ebglyss, Taltz |
| Glenmark Therapeutics INC. | $153.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $150.07 | 2020-2021 | |
| Epi Health, LLC | $147.48 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.66 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Dermavant Sciences, INC. | $102.14 | 2023-2024 | Vtama |
| Biofrontera INC. | $101.89 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $87.52 | 2020-2023 | Klisyri |
| Novartis Pharmaceuticals Corporation | $80.63 | 2019-2025 | |
| Ucb, INC. | $80.27 | 2024-2025 | Bimzelx |
| Botanix Sb INC | $61.59 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.41 | 2022-2024 | Spevigo |
| Sanofi-Aventis U.S. LLC | $43.69 | 2020-2021 | |
| Encore Dermatology INC. | $30.37 | 2019-2020 | |
| Celgene Corporation | $23.67 | 2019 | |
| Revance Therapeutics, INC. | $23.33 | 2024 | Daxxify |
| Taro Pharmaceuticals USA, INC. | $19.05 | 2019 | |
| Tactile Systems Technology INC | $18.35 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.88 | 2019 | |
| Sandoz INC. | $16.53 | 2019 | |
| Organon LLC | $13.14 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Weitzbuch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.